NEU 3.50% $14.05 neuren pharmaceuticals limited

NEWRON FAIL RETT, page-16

  1. 284 Posts.
    lightbulb Created with Sketch. 24

    Article about NEU competitors still in the race for Rett treatment.

    Rett failure sets up thin pipeline

    https://www.evaluate.com/vantage/articles/news/trial-results/rett-failure-sets-thin-pipeline
    Phase III pipeline for Rett treatment includes Trofinetide (Acadia), Anavex 2-73 (Anavex), Epidiolex (GW Pharmaceuticals). Indicated sales for each treatment ($US126m for Trofinetide) shown in article are less than I was expecting.


 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.